Organon & Co. (NYSE:OGN) Stock Holdings Lifted by Wealth Effects LLC

Wealth Effects LLC lifted its stake in shares of Organon & Co. (NYSE:OGN) by 13.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,578 shares of the company’s stock after acquiring an additional 7,160 shares during the quarter. Wealth Effects LLC’s holdings in Organon & Co. were worth $874,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of OGN. Pacer Advisors Inc. raised its holdings in Organon & Co. by 94,482.1% during the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock worth $166,391,000 after buying an additional 11,140,388 shares during the period. KBC Group NV boosted its stake in Organon & Co. by 66.6% in the 4th quarter. KBC Group NV now owns 12,899 shares of the company’s stock worth $192,000 after purchasing an additional 5,155 shares during the period. Blue Trust Inc. grew its position in Organon & Co. by 107.6% during the 4th quarter. Blue Trust Inc. now owns 7,599 shares of the company’s stock worth $113,000 after purchasing an additional 3,938 shares in the last quarter. Drive Wealth Management LLC acquired a new stake in Organon & Co. during the 4th quarter valued at $208,000. Finally, DGS Capital Management LLC purchased a new stake in shares of Organon & Co. in the fourth quarter valued at $235,000. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, TD Cowen upgraded Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $21.33.

Organon & Co. Stock Performance

Shares of OGN opened at $16.26 on Tuesday. The company has a market capitalization of $4.19 billion, a PE ratio of 3.23, a PEG ratio of 0.87 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The company’s 50 day moving average price is $15.39 and its 200 day moving average price is $18.03. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same quarter in the prior year, the firm earned $0.78 earnings per share. The company’s revenue was up 4.1% on a year-over-year basis. Research analysts expect that Organon & Co. will post 3.82 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th were paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.89%. The ex-dividend date was Tuesday, November 12th. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.